Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jun;36(3):619-627.
doi: 10.3803/EnM.2021.974. Epub 2021 Jun 10.

Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study

Mijin Kim  1 , Sun Wook Cho  2 , Young Joo Park  2 , Hwa Young Ahn  3 , Hee Sung Kim  4 , Yong Joon Suh  5 , Dughyun Choi  6 , Bu Kyung Kim  7 , Go Eun Yang  8 , Il-Seok Park  9 , Ka Hee Yi  10 , Chan Kwon Jung  11 , Bo Hyun Kim  1
Affiliations
Multicenter Study

Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study

Mijin Kim et al. Endocrinol Metab (Seoul). 2021 Jun.

Abstract

Background: We aimed to evaluate the clinicopathological features and biological behaviors of Korean thyroid cancer patients with rare variants of papillary thyroid carcinoma (PTC) to address the ambiguity regarding the prognostic consequences of these variants.

Methods: We retrospectively reviewed the medical records of 5,496 patients who underwent thyroid surgery for PTC, between January and December 2012, in nine tertiary hospitals. Rare PTC variants included tall cell (TCV), columnar cell (CCV), diffuse sclerosing (DSV), cribriform-morular (CMV), solid (SV), hobnail, and Warthin-like variants. Recurrence-free survival (RFS) was defined as the time from the date of thyroidectomy until recurrence.

Results: Rare variants accounted for 1.1% (n=63) of the PTC patients; with 0.9% TCV, 0.02% CCV, 0.1% DSV, 0.1% CMV, and 0.1% SV. The mean age of patients and primary tumor size were 42.1±13.1 years and 1.3±0.9 cm, respectively. Extrathyroidal extension and cervical lymph node metastasis were observed in 38 (60.3%) and 37 (58.7%) patients, respectively. Ultrasonographic findings revealed typical malignant features in most cases. During a median follow-up of 7 years, 6.3% of patients experienced a locoregional recurrence. The 5-year RFS rates were 71.4% in patients with DSV or SV, 95.9% for TCV, or CCV, and 100% for other variants. DSV emerged an independent risk factor associated with shorter RFS.

Conclusion: In this multicenter Korean cohort, rare variants accounted for 1.1% of all PTC cases, with TCV being the most frequent subtype. DSV emerged as a significant prognostic factor for RFS.

Keywords: Carcinoma, papillary; Prevalence; Prognosis; Recurrence; Thyroid neoplasms.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Forest plot for the overall pooled prevalence of rare variants of papillary thyroid carcinoma. The size of the box represents the weight given to each institution. The whiskers indicate the 95% confidence interval (CI).
Fig. 2
Fig. 2
(A) Recurrence-free survival curves according to each pathological variant. (B) Recurrence-free survival curves according to the American Thyroid Association classification: variants with aggressive outcomes include tall cell (TCV), columnar cell (CCV), and hobnail variants; those with less favorable outcomes include solid (SV) and diffuse sclerosing variants (DSV); and those with favorable outcomes include cribriform-morular (CMV), and Warthin-like variants.
Fig. 3
Fig. 3
Recurrence-free survival curves of patients with diffuse sclerosing variant (DSV) and others.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments] Cancer. 1998;83:2638–48. - PubMed
    1. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–42. - PubMed
    1. Nikiforov YE, Biddinger PW, Thompson LDR. Diagnostic pathology and molecular genetics of the thyroid. 2nd ed. Philadelphia: Wolters Kluwer; 2013.
    1. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–9. - PMC - PubMed
    1. Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 2016;101:264–74. - PMC - PubMed

Publication types